Your browser doesn't support javascript.
loading
Rapid Intraoperative Molecular Characterization of Glioma.
Shankar, Ganesh M; Francis, Joshua M; Rinne, Mikael L; Ramkissoon, Shakti H; Huang, Franklin W; Venteicher, Andrew S; Akama-Garren, Elliot H; Kang, Yun Jee; Lelic, Nina; Kim, James C; Brown, Loreal E; Charbonneau, Sarah K; Golby, Alexandra J; Sekhar Pedamallu, Chandra; Hoang, Mai P; Sullivan, Ryan J; Cherniack, Andrew D; Garraway, Levi A; Stemmer-Rachamimov, Anat; Reardon, David A; Wen, Patrick Y; Brastianos, Priscilla K; Curry, William T; Barker, Fred G; Hahn, William C; Nahed, Brian V; Ligon, Keith L; Louis, David N; Cahill, Daniel P; Meyerson, Matthew.
Afiliação
  • Shankar GM; Department of Neurosurgery, Massachusetts General Hospital, Boston2Cancer Program, Broad Institute, Cambridge, Massachusetts.
  • Francis JM; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Rinne ML; Cancer Program, Broad Institute, Cambridge, Massachusetts4Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston Massachusetts5Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Ramkissoon SH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts7Department of Pathology, Harvard Medical School, Boston, Massachusetts.
  • Huang FW; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Venteicher AS; Department of Neurosurgery, Massachusetts General Hospital, Boston8Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Akama-Garren EH; Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts.
  • Kang YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Lelic N; Department of Neurosurgery, Massachusetts General Hospital, Boston.
  • Kim JC; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Brown LE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Charbonneau SK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Golby AJ; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston Massachusetts10Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts.
  • Sekhar Pedamallu C; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Hoang MP; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Sullivan RJ; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Cherniack AD; Cancer Program, Broad Institute, Cambridge, Massachusetts.
  • Garraway LA; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Stemmer-Rachamimov A; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Reardon DA; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston Massachusetts5Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts.
  • Brastianos PK; Division of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts.
  • Curry WT; Department of Neurosurgery, Massachusetts General Hospital, Boston.
  • Barker FG; Department of Neurosurgery, Massachusetts General Hospital, Boston.
  • Hahn WC; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts.
  • Nahed BV; Department of Neurosurgery, Massachusetts General Hospital, Boston.
  • Ligon KL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts6Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts7Department of Pathology, Harvard Medical School, Boston, Massachusetts12Center for Molecular On.
  • Louis DN; Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
  • Cahill DP; Department of Neurosurgery, Massachusetts General Hospital, Boston.
  • Meyerson M; Cancer Program, Broad Institute, Cambridge, Massachusetts3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston Massachusetts7Department of Pathology, Harvard Medical School, Boston, Massachusetts.
JAMA Oncol ; 1(5): 662-7, 2015 Aug.
Article em En | MEDLINE | ID: mdl-26181761
ABSTRACT
IMPORTANCE Conclusive intraoperative pathologic confirmation of diffuse infiltrative glioma guides the decision to pursue definitive neurosurgical resection. Establishing the intraoperative diagnosis by histologic analysis can be difficult in low-cellularity infiltrative gliomas. Therefore, we developed a rapid and sensitive genotyping assay to detect somatic single-nucleotide variants in the telomerase reverse transcriptase (TERT) promoter and isocitrate dehydrogenase 1 (IDH1). OBSERVATIONS This assay was applied to tissue samples from 190 patients with diffuse gliomas, including archived fixed and frozen specimens and tissue obtained intraoperatively. Results demonstrated 96% sensitivity (95% CI, 90%-99%) and 100% specificity (95% CI, 95%-100%) for World Health Organization grades II and III gliomas. In a series of live cases, glioma-defining mutations could be identified within 60 minutes, which could facilitate the diagnosis in an intraoperative timeframe. CONCLUSIONS AND RELEVANCE The genotyping method described herein can establish the diagnosis of low-cellularity tumors like glioma and could be adapted to the point-of-care diagnosis of other lesions that are similarly defined by highly recurrent somatic mutations.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Biomarcadores Tumorais / Telomerase / Polimorfismo de Nucleotídeo Único / Técnicas de Diagnóstico Molecular / Glioma / Isocitrato Desidrogenase Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: JAMA Oncol Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Biomarcadores Tumorais / Telomerase / Polimorfismo de Nucleotídeo Único / Técnicas de Diagnóstico Molecular / Glioma / Isocitrato Desidrogenase Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Female / Humans / Male Idioma: En Revista: JAMA Oncol Ano de publicação: 2015 Tipo de documento: Article